xnegate
2021-08-13
Hi
ARK Investment Buys the Dips in 1Life, Berkeley Lights, Signify Health<blockquote>ARK Investment 逢低买入 1Life、Berkeley Lights、Signify Health</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":894235227,"tweetId":"894235227","gmtCreate":1628827986869,"gmtModify":1631888738647,"author":{"id":4090707232019850,"idStr":"4090707232019850","authorId":4090707232019850,"authorIdStr":"4090707232019850","name":"xnegate","avatar":"https://static.tigerbbs.com/7549d1578f4d67f05cd97a41e6bfb844","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":7,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Hi</p></body></html>","htmlText":"<html><head></head><body><p>Hi</p></body></html>","text":"Hi","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/894235227","repostId":1191538365,"repostType":4,"repost":{"id":"1191538365","kind":"news","pubTimestamp":1628825496,"share":"https://www.laohu8.com/m/news/1191538365?lang=zh_CN&edition=full","pubTime":"2021-08-13 11:31","market":"us","language":"en","title":"ARK Investment Buys the Dips in 1Life, Berkeley Lights, Signify Health<blockquote>ARK Investment 逢低买入 1Life、Berkeley Lights、Signify Health</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1191538365","media":"24/7 wall street","summary":"Cathie Wood and her ARK Investment Management firm have made no secret of their investment strategy:","content":"<p>Cathie Wood and her ARK Investment Management firm have made no secret of their investment strategy: find those companies that have a product or service that could change the way the world works. ARK calls that “disruptive innovation.”</p><p><blockquote>凯西·伍德和她的方舟投资管理公司毫不掩饰他们的投资策略：寻找那些拥有能够改变世界运作方式的产品或服务的公司。方舟评级 “颠覆性创新”</blockquote></p><p> To support those investments, ARK also invests in what Wood has called “cash-like innovation stocks,” such as <a href=\"https://laohu8.com/S/AAPL\">Apple</a>, Tesla, <a href=\"https://laohu8.com/S/GOOG\">Alphabet</a> and <a href=\"https://laohu8.com/S/NFLX\">Netflix</a>, because ARK’s funds are not allowed to hold cash. She told CNBC in May, “During a period of volatility like we’ve just seen, we will sell those stocks and move into either our more pure-play or earlier-stage innovation companies that are being hurt by risk-off.”</p><p><blockquote>为了支持这些投资，ARK 还投资了伍德所说的 “类现金创新股票”，例如<a href=\"https://laohu8.com/S/AAPL\">苹果</a>, 特斯拉,<a href=\"https://laohu8.com/S/GOOG\">Alphabet</a>和<a href=\"https://laohu8.com/S/NFLX\">网飞</a>，因为方舟的基金不允许持有现金。她在 5 月份告诉 CNBC：“在像我们刚刚看到的这样的波动时期，我们将卖出这些股票，转入我们更纯粹的股票或因避险而受到伤害的早期创新公司。”</blockquote></p><p> Walking the talk, ARK funds sold all 594,039 Apple shares they owned in March during the June quarter and about 22,000 Netflix shares and 80,000 Tesla shares in the same period.</p><p><blockquote>方舟基金言出必行，在 6 月份季度出售了他们在 3 月份持有的全部 594,039 股苹果股票，同期出售了约 22,000 股 Netflix 股票和 80,000 股特斯拉股票。</blockquote></p><p> Here are three health care companies that ARK invested in during the June quarter.</p><p><blockquote>以下是 ARK 在 6 月份季度投资的三家医疗保健公司。</blockquote></p><p> <b>1Life</b></p><p><blockquote><b>1生命</b></blockquote></p><p> 1Life <a href=\"https://laohu8.com/S/HCSG\">Healthcare</a> Inc. (NASDAQ: ONEM) has lost about 57% of its market value since peaking at $7.81 billion in February. At the end of March, the ARK Genomic Revolution ETF (NYSEARCA: ARKG) held 3.5 million shares of 1Life. At the end of June, this fund’s stake in the company had increased to 4.3 million shares.</p><p><blockquote>1生命<a href=\"https://laohu8.com/S/HCSG\">医疗保健</a>Inc.（纳斯达克股票代码：ONEM）自 2 月份达到 78.1 亿美元的峰值以来，其市值已损失约 57%。截至3月底，ARK Genomic Revolution ETF（NYSEARCA：ARKG）持有350万股1Life股票。截至 6 月底，该基金持有的公司股份已增至 430 万股。</blockquote></p><p> In May, ARK analyst Simon Barnett had this comment on 1Life:</p><p><blockquote>五月份，ARK 分析师 Simon Barnett 在 1Life 上发表了这样的评论：</blockquote></p><p> One [<a href=\"https://laohu8.com/S/HR\">Healthcare</a>]’s “click-and-mortar” platform spans both digital and in-person primary care and incorporates its own EHR [electronic health record] system. It also compensates physicians with salaries instead of fees for service and removes the burden of administrative tasks that devour so much of a physician’s day. In our view, this model could be fertile ground for value-based genetic testing services. On Thursday, Barclays initiated coverage on 1Life at Overweight with a price target of $32. Ten of 12 analysts covering the company rate the shares a Buy or Strong Buy, and the other two have a Hold rating. Barclays estimated a long-term growth target on the stock in the mid-20% range, based on an enterprise value-to-sales multiple. The median price target on the stock is $40.50, implying upside potential to a current price of around $24.20 of 67%. At the high price target of $63, the upside potential on the stock is 160%.</p><p><blockquote>一[<a href=\"https://laohu8.com/S/HR\">医疗保健</a>]的 “点击即可 ”平台涵盖数字和面对面的初级保健，并整合了自己的 EHR（电子健康记录）系统。它还用工资而不是服务费来补偿医生，并消除了耗费医生大量时间的行政工作负担。我们认为，这种模式可能是基于价值的基因检测服务的沃土。周四，巴克莱银行开始对跑赢大盘 1Life 进行投资，目标价为 32 美元。研究该公司的 12 名分析师中有 10 名将该股评级为买入或强力买入，另外两名分析师给予持有评级。巴克莱根据企业价值销售额倍数估计该股的长期增长目标在 20% 左右。该股的目标价中位数为 40.50 美元，这意味着当前价格在 24.20 美元左右的上涨潜力为 67%。在63美元的高目标价下，该股的上涨潜力为160%。</blockquote></p><p> 1Life’s shares traded up less than 2% late Thursday morning, at $24.63 in a 52-week range of $23.65 to $58.82. The stock trades about 1.5 million shares a day on average.</p><p><blockquote>周四上午晚些时候，1Life 的股价上涨不到 2%，报 24.63 美元，52 周区间为 23.65 美元至 58.82 美元。该股平均每天交易量约为150万股。</blockquote></p><p> <b>Signify Health</b></p><p><blockquote><b>表示健康</b></blockquote></p><p> Since its market cap peaked at $6.95 billion in late June, Signify Health Inc. (NYSE: SGFY) has dropped about 21% of its value. At the end of March, the ARKG fund held about 1.7 million shares in the company, and at the end of June, it had more than doubled its stake just over 4 million shares. On Wednesday, the <a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a> (NYSEARCA: ARKK) initiated a position in Signify, adding 807,917 shares at a cost of $24.30 per share. Including additions to ARKG since June, ARK Invest’s total stake in the company is about 7.35 million shares, valued at $178.58 million.</p><p><blockquote>自 6 月底市值达到 69.5 亿美元的峰值以来，Signify Health Inc.（纽约证券交易所股票代码：SGFY）的市值已下跌约 21%。截至3月底，ARKG基金持有该公司约170万股股票，截至6月底，其持股量增加了一倍多，略高于400万股。周三，<a href=\"https://laohu8.com/S/ARKK\">方舟创新ETF</a>（NYSEARCA：ARKK）开始建仓 Signify，以每股 24.30 美元的成本增持 807,917 股股票。包括自 6 月份以来增持的 ARKG 股份在内，ARK Invest 持有的公司股份总数约为 735 万股，价值 1.7858 亿美元。</blockquote></p><p> Signify Health operates a health care platform that offers services primarily for Medicare Advantage plans that include health evaluations, diagnostic screening and other services plus a platform to manage payments.</p><p><blockquote>Signify Health运营一个医疗保健平台，主要为Medicare Advantage计划提供服务，包括健康评估、诊断筛查和其他服务，以及一个管理付款的平台。</blockquote></p><p> Barclays upgraded the company’s stock from Equal Weight to Overweight and maintained its $30 price target. At the median price target of $32, the upside potential based on a current price of about $25.00 is 28%. At the high price target of $42, the upside potential is 68%. Only eight brokerages cover the firm, but six rate the stock a Buy or Strong Buy.</p><p><blockquote>巴克莱银行将该公司股票评级从同等权重上调至跑赢大盘，并维持 30 美元的目标价不变。中位目标价为 32 美元，基于当前约 25.00 美元的价格，上涨潜力为 28%。在 42 美元的高目标价下，上涨潜力为 68%。只有八家券商为该公司提供服务，但有六家券商将该股评级为买入或强力买入。</blockquote></p><p> Shares traded up 3.3% to $25.05 on Thursday. The stock’s 52-week range is $22.13 to $40.79, and it trades just over half a million shares a day.</p><p><blockquote>周四股价上涨 3.3%，至 25.05 美元。该股的 52 周区间为 22.13 美元至 40.79 美元，每天的交易量略高于 50 万股。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/BLI\">Berkeley Lights</a></b></p><p><blockquote><b><a href=\"https://laohu8.com/S/BLI\">伯克利之光</a></b></blockquote></p><p> Berkeley Lights Inc. (NASDAQ: BLI) posted a peak market cap of $6.82 billion in late December of last year. When markets closed on Wednesday, the company’s market cap had fallen by 57% to around $2.92 billion. At the end of the first quarter of this year, both the ARKG and ARKK funds combined held about 5.1 million shares of the company’s stock. At the end of June, the holdings totaled about 6.9 million shares. As of Wednesday’s close, ARK’s total holdings were just under 7 million shares.</p><p><blockquote>Berkeley Lights Inc.（纳斯达克股票代码：BLI）去年 12 月底公布的市值峰值为 68.2 亿美元。周三收盘时，该公司的市值下跌了 57%，约为 29.2 亿美元。截至今年第一季度末，ARKG 和 ARKK 基金合计持有该公司股票约 510 万股。截至6月底，持股总数约为690万股。截至周三收盘，ARK 的总持股略低于 700 万股。</blockquote></p><p> Berkeley Lights is a biotech firm that offers an integrated hardware and software platform for the development and commercialization of biotherapeutics and other cell-based products. The company failed to meet expectations for both its quarterly loss per share and quarterly revenue. As other investors bailed, ARK bought the dip and acquired about 340,000 shares of the company’s stock.</p><p><blockquote>Berkeley Lights 是一家生物技术公司，为生物疗法和其他基于细胞的产品的开发和商业化提供集成的硬件和软件平台。该公司季度每股亏损和季度收入均未达到预期。由于其他投资者纷纷退出，ARK 逢低买入，收购了该公司股票约 34 万股。</blockquote></p><p></p><p> <a href=\"https://laohu8.com/S/MS\">Morgan Stanley</a> kept its Equal Weight rating on the stock but reduced its 12-month price target from $73 to $66. Analysts at BTIG maintained their Buy rating on the stock but lowered their price target from $70 to $65. In a note to investors, BTIG commented:</p><p><blockquote><a href=\"https://laohu8.com/S/MS\">摩根士丹利</a>维持对该股的同等权重评级，但将 12 个月目标价从 73 美元下调至 66 美元。BTIG 分析师维持该股的买入评级，但将目标价从 70 美元下调至 65 美元。BTIG 在给投资者的一份报告中评论道：</blockquote></p><p> We recommend shares of BLI on unfounded weakness (shares are down 63% from its peak in December despite strong operational execution). We view BLI as an emerging global leader in helping researchers characterize live cells for accelerating development of biotherapeutics and other cell-based products, from antibody therapeutics and cell therapy to gene therapy and synthetic biology. Shares traded up around 1% on Thursday, at $40.08 in a 52-week range of $35.51 to $113.53. The stock trades around 800,000 shares a day.</p><p><blockquote>我们推荐 BLI 股票，理由是没有根据的疲软（尽管运营执行力强劲，但股价较 12 月份的峰值下跌了 63%）。我们认为 BLI 是帮助研究人员表征活细胞以加速生物疗法和其他基于细胞的产品（从抗体疗法和细胞疗法到基因疗法和合成生物学）开发的新兴全球领导者。周四股价上涨约 1%，至 40.08 美元，52 周区间为 35.51 美元至 113.53 美元。该股每天交易量约为 80 万股。</blockquote></p><p></p>","source":"lsy1620372341666","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ARK Investment Buys the Dips in 1Life, Berkeley Lights, Signify Health<blockquote>ARK Investment 逢低买入 1Life、Berkeley Lights、Signify Health</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nARK Investment Buys the Dips in 1Life, Berkeley Lights, Signify Health<blockquote>ARK Investment 逢低买入 1Life、Berkeley Lights、Signify Health</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">24/7 wall street</strong><span class=\"h-time small\">2021-08-13 11:31</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Cathie Wood and her ARK Investment Management firm have made no secret of their investment strategy: find those companies that have a product or service that could change the way the world works. ARK calls that “disruptive innovation.”</p><p><blockquote>凯西·伍德和她的方舟投资管理公司毫不掩饰他们的投资策略：寻找那些拥有能够改变世界运作方式的产品或服务的公司。方舟评级 “颠覆性创新”</blockquote></p><p> To support those investments, ARK also invests in what Wood has called “cash-like innovation stocks,” such as <a href=\"https://laohu8.com/S/AAPL\">Apple</a>, Tesla, <a href=\"https://laohu8.com/S/GOOG\">Alphabet</a> and <a href=\"https://laohu8.com/S/NFLX\">Netflix</a>, because ARK’s funds are not allowed to hold cash. She told CNBC in May, “During a period of volatility like we’ve just seen, we will sell those stocks and move into either our more pure-play or earlier-stage innovation companies that are being hurt by risk-off.”</p><p><blockquote>为了支持这些投资，ARK 还投资了伍德所说的 “类现金创新股票”，例如<a href=\"https://laohu8.com/S/AAPL\">苹果</a>, 特斯拉,<a href=\"https://laohu8.com/S/GOOG\">Alphabet</a>和<a href=\"https://laohu8.com/S/NFLX\">网飞</a>，因为方舟的基金不允许持有现金。她在 5 月份告诉 CNBC：“在像我们刚刚看到的这样的波动时期，我们将卖出这些股票，转入我们更纯粹的股票或因避险而受到伤害的早期创新公司。”</blockquote></p><p> Walking the talk, ARK funds sold all 594,039 Apple shares they owned in March during the June quarter and about 22,000 Netflix shares and 80,000 Tesla shares in the same period.</p><p><blockquote>方舟基金言出必行，在 6 月份季度出售了他们在 3 月份持有的全部 594,039 股苹果股票，同期出售了约 22,000 股 Netflix 股票和 80,000 股特斯拉股票。</blockquote></p><p> Here are three health care companies that ARK invested in during the June quarter.</p><p><blockquote>以下是 ARK 在 6 月份季度投资的三家医疗保健公司。</blockquote></p><p> <b>1Life</b></p><p><blockquote><b>1生命</b></blockquote></p><p> 1Life <a href=\"https://laohu8.com/S/HCSG\">Healthcare</a> Inc. (NASDAQ: ONEM) has lost about 57% of its market value since peaking at $7.81 billion in February. At the end of March, the ARK Genomic Revolution ETF (NYSEARCA: ARKG) held 3.5 million shares of 1Life. At the end of June, this fund’s stake in the company had increased to 4.3 million shares.</p><p><blockquote>1生命<a href=\"https://laohu8.com/S/HCSG\">医疗保健</a>Inc.（纳斯达克股票代码：ONEM）自 2 月份达到 78.1 亿美元的峰值以来，其市值已损失约 57%。截至3月底，ARK Genomic Revolution ETF（NYSEARCA：ARKG）持有350万股1Life股票。截至 6 月底，该基金持有的公司股份已增至 430 万股。</blockquote></p><p> In May, ARK analyst Simon Barnett had this comment on 1Life:</p><p><blockquote>五月份，ARK 分析师 Simon Barnett 在 1Life 上发表了这样的评论：</blockquote></p><p> One [<a href=\"https://laohu8.com/S/HR\">Healthcare</a>]’s “click-and-mortar” platform spans both digital and in-person primary care and incorporates its own EHR [electronic health record] system. It also compensates physicians with salaries instead of fees for service and removes the burden of administrative tasks that devour so much of a physician’s day. In our view, this model could be fertile ground for value-based genetic testing services. On Thursday, Barclays initiated coverage on 1Life at Overweight with a price target of $32. Ten of 12 analysts covering the company rate the shares a Buy or Strong Buy, and the other two have a Hold rating. Barclays estimated a long-term growth target on the stock in the mid-20% range, based on an enterprise value-to-sales multiple. The median price target on the stock is $40.50, implying upside potential to a current price of around $24.20 of 67%. At the high price target of $63, the upside potential on the stock is 160%.</p><p><blockquote>一[<a href=\"https://laohu8.com/S/HR\">医疗保健</a>]的 “点击即可 ”平台涵盖数字和面对面的初级保健，并整合了自己的 EHR（电子健康记录）系统。它还用工资而不是服务费来补偿医生，并消除了耗费医生大量时间的行政工作负担。我们认为，这种模式可能是基于价值的基因检测服务的沃土。周四，巴克莱银行开始对跑赢大盘 1Life 进行投资，目标价为 32 美元。研究该公司的 12 名分析师中有 10 名将该股评级为买入或强力买入，另外两名分析师给予持有评级。巴克莱根据企业价值销售额倍数估计该股的长期增长目标在 20% 左右。该股的目标价中位数为 40.50 美元，这意味着当前价格在 24.20 美元左右的上涨潜力为 67%。在63美元的高目标价下，该股的上涨潜力为160%。</blockquote></p><p> 1Life’s shares traded up less than 2% late Thursday morning, at $24.63 in a 52-week range of $23.65 to $58.82. The stock trades about 1.5 million shares a day on average.</p><p><blockquote>周四上午晚些时候，1Life 的股价上涨不到 2%，报 24.63 美元，52 周区间为 23.65 美元至 58.82 美元。该股平均每天交易量约为150万股。</blockquote></p><p> <b>Signify Health</b></p><p><blockquote><b>表示健康</b></blockquote></p><p> Since its market cap peaked at $6.95 billion in late June, Signify Health Inc. (NYSE: SGFY) has dropped about 21% of its value. At the end of March, the ARKG fund held about 1.7 million shares in the company, and at the end of June, it had more than doubled its stake just over 4 million shares. On Wednesday, the <a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a> (NYSEARCA: ARKK) initiated a position in Signify, adding 807,917 shares at a cost of $24.30 per share. Including additions to ARKG since June, ARK Invest’s total stake in the company is about 7.35 million shares, valued at $178.58 million.</p><p><blockquote>自 6 月底市值达到 69.5 亿美元的峰值以来，Signify Health Inc.（纽约证券交易所股票代码：SGFY）的市值已下跌约 21%。截至3月底，ARKG基金持有该公司约170万股股票，截至6月底，其持股量增加了一倍多，略高于400万股。周三，<a href=\"https://laohu8.com/S/ARKK\">方舟创新ETF</a>（NYSEARCA：ARKK）开始建仓 Signify，以每股 24.30 美元的成本增持 807,917 股股票。包括自 6 月份以来增持的 ARKG 股份在内，ARK Invest 持有的公司股份总数约为 735 万股，价值 1.7858 亿美元。</blockquote></p><p> Signify Health operates a health care platform that offers services primarily for Medicare Advantage plans that include health evaluations, diagnostic screening and other services plus a platform to manage payments.</p><p><blockquote>Signify Health运营一个医疗保健平台，主要为Medicare Advantage计划提供服务，包括健康评估、诊断筛查和其他服务，以及一个管理付款的平台。</blockquote></p><p> Barclays upgraded the company’s stock from Equal Weight to Overweight and maintained its $30 price target. At the median price target of $32, the upside potential based on a current price of about $25.00 is 28%. At the high price target of $42, the upside potential is 68%. Only eight brokerages cover the firm, but six rate the stock a Buy or Strong Buy.</p><p><blockquote>巴克莱银行将该公司股票评级从同等权重上调至跑赢大盘，并维持 30 美元的目标价不变。中位目标价为 32 美元，基于当前约 25.00 美元的价格，上涨潜力为 28%。在 42 美元的高目标价下，上涨潜力为 68%。只有八家券商为该公司提供服务，但有六家券商将该股评级为买入或强力买入。</blockquote></p><p> Shares traded up 3.3% to $25.05 on Thursday. The stock’s 52-week range is $22.13 to $40.79, and it trades just over half a million shares a day.</p><p><blockquote>周四股价上涨 3.3%，至 25.05 美元。该股的 52 周区间为 22.13 美元至 40.79 美元，每天的交易量略高于 50 万股。</blockquote></p><p> <b><a href=\"https://laohu8.com/S/BLI\">Berkeley Lights</a></b></p><p><blockquote><b><a href=\"https://laohu8.com/S/BLI\">伯克利之光</a></b></blockquote></p><p> Berkeley Lights Inc. (NASDAQ: BLI) posted a peak market cap of $6.82 billion in late December of last year. When markets closed on Wednesday, the company’s market cap had fallen by 57% to around $2.92 billion. At the end of the first quarter of this year, both the ARKG and ARKK funds combined held about 5.1 million shares of the company’s stock. At the end of June, the holdings totaled about 6.9 million shares. As of Wednesday’s close, ARK’s total holdings were just under 7 million shares.</p><p><blockquote>Berkeley Lights Inc.（纳斯达克股票代码：BLI）去年 12 月底公布的市值峰值为 68.2 亿美元。周三收盘时，该公司的市值下跌了 57%，约为 29.2 亿美元。截至今年第一季度末，ARKG 和 ARKK 基金合计持有该公司股票约 510 万股。截至6月底，持股总数约为690万股。截至周三收盘，ARK 的总持股略低于 700 万股。</blockquote></p><p> Berkeley Lights is a biotech firm that offers an integrated hardware and software platform for the development and commercialization of biotherapeutics and other cell-based products. The company failed to meet expectations for both its quarterly loss per share and quarterly revenue. As other investors bailed, ARK bought the dip and acquired about 340,000 shares of the company’s stock.</p><p><blockquote>Berkeley Lights 是一家生物技术公司，为生物疗法和其他基于细胞的产品的开发和商业化提供集成的硬件和软件平台。该公司季度每股亏损和季度收入均未达到预期。由于其他投资者纷纷退出，ARK 逢低买入，收购了该公司股票约 34 万股。</blockquote></p><p></p><p> <a href=\"https://laohu8.com/S/MS\">Morgan Stanley</a> kept its Equal Weight rating on the stock but reduced its 12-month price target from $73 to $66. Analysts at BTIG maintained their Buy rating on the stock but lowered their price target from $70 to $65. In a note to investors, BTIG commented:</p><p><blockquote><a href=\"https://laohu8.com/S/MS\">摩根士丹利</a>维持对该股的同等权重评级，但将 12 个月目标价从 73 美元下调至 66 美元。BTIG 分析师维持该股的买入评级，但将目标价从 70 美元下调至 65 美元。BTIG 在给投资者的一份报告中评论道：</blockquote></p><p> We recommend shares of BLI on unfounded weakness (shares are down 63% from its peak in December despite strong operational execution). We view BLI as an emerging global leader in helping researchers characterize live cells for accelerating development of biotherapeutics and other cell-based products, from antibody therapeutics and cell therapy to gene therapy and synthetic biology. Shares traded up around 1% on Thursday, at $40.08 in a 52-week range of $35.51 to $113.53. The stock trades around 800,000 shares a day.</p><p><blockquote>我们推荐 BLI 股票，理由是没有根据的疲软（尽管运营执行力强劲，但股价较 12 月份的峰值下跌了 63%）。我们认为 BLI 是帮助研究人员表征活细胞以加速生物疗法和其他基于细胞的产品（从抗体疗法和细胞疗法到基因疗法和合成生物学）开发的新兴全球领导者。周四股价上涨约 1%，至 40.08 美元，52 周区间为 35.51 美元至 113.53 美元。该股每天交易量约为 80 万股。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://247wallst.com/healthcare-business/2021/08/12/ark-investment-buys-the-dips-in-1life-berkeley-lights-signify-health/\">24/7 wall street</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SGFY":"Signify Health, Inc.","ARKK":"ARK Innovation ETF"},"source_url":"https://247wallst.com/healthcare-business/2021/08/12/ark-investment-buys-the-dips-in-1life-berkeley-lights-signify-health/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191538365","content_text":"Cathie Wood and her ARK Investment Management firm have made no secret of their investment strategy: find those companies that have a product or service that could change the way the world works. ARK calls that “disruptive innovation.”\nTo support those investments, ARK also invests in what Wood has called “cash-like innovation stocks,” such as Apple, Tesla, Alphabet and Netflix, because ARK’s funds are not allowed to hold cash. She told CNBC in May, “During a period of volatility like we’ve just seen, we will sell those stocks and move into either our more pure-play or earlier-stage innovation companies that are being hurt by risk-off.”\nWalking the talk, ARK funds sold all 594,039 Apple shares they owned in March during the June quarter and about 22,000 Netflix shares and 80,000 Tesla shares in the same period.\nHere are three health care companies that ARK invested in during the June quarter.\n1Life\n1Life Healthcare Inc. (NASDAQ: ONEM) has lost about 57% of its market value since peaking at $7.81 billion in February. At the end of March, the ARK Genomic Revolution ETF (NYSEARCA: ARKG) held 3.5 million shares of 1Life. At the end of June, this fund’s stake in the company had increased to 4.3 million shares.\nIn May, ARK analyst Simon Barnett had this comment on 1Life:\n\n One [Healthcare]’s “click-and-mortar” platform spans both digital and in-person primary care and incorporates its own EHR [electronic health record] system. It also compensates physicians with salaries instead of fees for service and removes the burden of administrative tasks that devour so much of a physician’s day. In our view, this model could be fertile ground for value-based genetic testing services.\n\nOn Thursday, Barclays initiated coverage on 1Life at Overweight with a price target of $32. Ten of 12 analysts covering the company rate the shares a Buy or Strong Buy, and the other two have a Hold rating. Barclays estimated a long-term growth target on the stock in the mid-20% range, based on an enterprise value-to-sales multiple. The median price target on the stock is $40.50, implying upside potential to a current price of around $24.20 of 67%. At the high price target of $63, the upside potential on the stock is 160%.\n1Life’s shares traded up less than 2% late Thursday morning, at $24.63 in a 52-week range of $23.65 to $58.82. The stock trades about 1.5 million shares a day on average.\nSignify Health\nSince its market cap peaked at $6.95 billion in late June, Signify Health Inc. (NYSE: SGFY) has dropped about 21% of its value. At the end of March, the ARKG fund held about 1.7 million shares in the company, and at the end of June, it had more than doubled its stake just over 4 million shares. On Wednesday, the ARK Innovation ETF (NYSEARCA: ARKK) initiated a position in Signify, adding 807,917 shares at a cost of $24.30 per share. Including additions to ARKG since June, ARK Invest’s total stake in the company is about 7.35 million shares, valued at $178.58 million.\nSignify Health operates a health care platform that offers services primarily for Medicare Advantage plans that include health evaluations, diagnostic screening and other services plus a platform to manage payments.\nBarclays upgraded the company’s stock from Equal Weight to Overweight and maintained its $30 price target. At the median price target of $32, the upside potential based on a current price of about $25.00 is 28%. At the high price target of $42, the upside potential is 68%. Only eight brokerages cover the firm, but six rate the stock a Buy or Strong Buy.\nShares traded up 3.3% to $25.05 on Thursday. The stock’s 52-week range is $22.13 to $40.79, and it trades just over half a million shares a day.\nBerkeley Lights\nBerkeley Lights Inc. (NASDAQ: BLI) posted a peak market cap of $6.82 billion in late December of last year. When markets closed on Wednesday, the company’s market cap had fallen by 57% to around $2.92 billion. At the end of the first quarter of this year, both the ARKG and ARKK funds combined held about 5.1 million shares of the company’s stock. At the end of June, the holdings totaled about 6.9 million shares. As of Wednesday’s close, ARK’s total holdings were just under 7 million shares.\nBerkeley Lights is a biotech firm that offers an integrated hardware and software platform for the development and commercialization of biotherapeutics and other cell-based products. The company failed to meet expectations for both its quarterly loss per share and quarterly revenue. As other investors bailed, ARK bought the dip and acquired about 340,000 shares of the company’s stock.\nMorgan Stanley kept its Equal Weight rating on the stock but reduced its 12-month price target from $73 to $66. Analysts at BTIG maintained their Buy rating on the stock but lowered their price target from $70 to $65. In a note to investors, BTIG commented:\n\n We recommend shares of BLI on unfounded weakness (shares are down 63% from its peak in December despite strong operational execution). We view BLI as an emerging global leader in helping researchers characterize live cells for accelerating development of biotherapeutics and other cell-based products, from antibody therapeutics and cell therapy to gene therapy and synthetic biology.\n\nShares traded up around 1% on Thursday, at $40.08 in a 52-week range of $35.51 to $113.53. The stock trades around 800,000 shares a day.","news_type":1,"symbols_score_info":{"ARKK":0.9,"SGFY":0.9,"BLI":0.9}},"isVote":1,"tweetType":1,"viewCount":1743,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/894235227"}
精彩评论